BioXcel Therapeutics, Inc. Operating Lease, Liability, Current
BioXcel Therapeutics, Inc. (BTAI) had Operating Lease, Liability, Current of $65.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-03-27
- 2025-12-31: Operating Lease, Liability, Current $65.00K.
- 2025-09-30: Operating Lease, Liability, Current $161.00K.
- 2025-06-30: Operating Lease, Liability, Current $256.00K.
- 2025-03-31: Operating Lease, Liability, Current $350.00K.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2025-12-31 | $65.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $161.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $256.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $350.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $374.00K 10-K · filed 2025-03-28 |
| 2024-09-30 | $368.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $361.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $353.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $346.00K 10-K · filed 2024-03-22 |
| 2023-09-30 | $339.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $332.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $325.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $319.00K 10-K · filed 2023-03-16 |
| 2022-09-30 | $312.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $306.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $299.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $293.00K 10-K · filed 2022-03-11 |
| 2021-09-30 | $287.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $281.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $275.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $237.00K 10-Q · filed 2021-11-10 |
| 2020-09-30 | $210.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $194.00K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $192.00K 10-Q · filed 2020-05-12 |
| 2019-12-31 | $164.00K 10-K · filed 2020-03-09 |
| 2019-09-30 | $161.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $158.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $156.00K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |